Login to Your Account



Biogen Idec Starts Phase III NHL Trial Of Galiximab Plus Rituxan

By Trista Morrison


Friday, January 26, 2007

Contributing Writer

In treating cancer, two drugs often prove to be better than one. By that reasoning, Biogen Idec Inc. initiated a Phase III trial of the anti-CD80 monoclonal antibody galiximab combined with the anti-CD20 monoclonal antibody Rituxan (rituximab).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription